The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that is a major therapeutic target for the treatment of type 2 diabetes. Activation of this receptor promotes insulin secretion and blood glucose regulation. The GLP-1R can initiate signaling through several intracellular pathways upon activation by GLP-1. GLP-1R ligands that preferentially stimulate subsets among the natural signaling pathways (''biased agonists") could be useful as tools for elucidating the consequences of specific pathways and might engender therapeutic agents with tailored effects. Using HEK-293 cells recombinantly expressing human GLP-1R, we have previously reported that backbone modification of GLP-1, via replacement of selected a-amino acid residues with b-amino acid residues, generates GLP-1 analogues with distinctive preferences for promoting G protein activation versus b-arrestin recruitment. Here, we have explored the influence of cell background across these two parameters and expanded our analysis to include affinity and other key signaling pathways (intracellular calcium mobilization and ERK phosphorylation) using recombinant human GLP-1R expressed in a CHO cell background, which has been used extensively to demonstrate biased agonism of GLP-1R ligands. The new data indicate that a/b-peptide analogues of GLP-1 exhibit a range of distinct bias profiles relative to GLP-1 and that broad assessment of signaling endpoints is required to reveal the spectrum of behavior of modified peptides.
Introduction
Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance, decreased insulin production, and the gradual failure of pancreatic b cells [1] . These features result in consistently high glucose levels in patients [2] , a condition that can lead to severe complications and premature death [1] . Current diabetes treatments include insulin-sensitizing agents [3] , exogenous insulin [4] , and, more recently, agonists of the glucagon-like peptide 1 receptor (GLP-1R) [5] . This receptor has garnered interest because of its role not only in regulating blood glucose levels, but also in promoting other cellular and physiological outcomes that are impaired in diabetic patients; GLP-1R agonists increase satiety, decrease gastric emptying and enhance b cell health [6] . The most potent native agonists of the GLP-1R are two closely related forms of the glucagon-like peptide-1, which are designated GLP-1 NH 2 and GLP-1 . Both are generated via processing of a longer precursor. These two peptides are referred to collectively as ''GLP-1" below.
Binding of GLP-1 to the extracellular surface of the GLP-1R promotes recruitment of several G proteins, including Ga s , Ga q , Ga i and Ga o [7] [8] [9] , as well as b-arrestin-1 and b-arrestin-2, to the cytoplasmic surface of the receptor [9, 10] . While Gs stimulation is principally linked to activation of adenylate cyclase and cAMP formation, the canonical driver of GLP-1-stimulated insulin secretion [6] , G s , G q and G i/o proteins can each lead to mobilization of intracellular calcium and/or ERK1/2 phosphorylation, in a ligandand cell-type-specific manner [7] [8] [9] . b-Arrestins can modulate cell proliferation and apoptosis, at least in part through activation of MAPKs such as ERK1/2 [11, 12] , while also playing a role in b-cell-mediated insulin secretion [11] .
The pleiotropy of signaling initiated by GPCRs allows for the potential of individual ligands of a specific receptor to generate distinct profiles of response, a phenomenon termed biased agonism [13] [14] [15] . At a receptor level, bias is engendered by unique interactions between ligands and the receptor that, in turn, can stabilize distinct ensembles of conformations that promote differential engagement with effector proteins (e.g., a G protein or a b-arrestin) [16, 17] . Biased agonists have received substantial attention for their potential as tools for elucidating GPCR signaling mechanisms, and as therapeutic candidates that might exert focused physiological effects by minimizing activation of pathways other than those that offer therapeutic benefit [15, 18, 19] .
Oxyntomodulin, a natural ligand for the GLP-1R, and the clinically approved agonist exendin-4 exhibit bias in canonical signaling pathways and for arrestin recruitment, relative to GLP-1 in recombinant expression systems [9, 20, 21, 25] and in insulinoma cells that natively express the GLP-1R [9] . Moreover, an N-terminally modified form of exendin-4, termed exendin P5, that exhibited bias away from arrestin recruitment (i.e., G protein-biased relative to exendin-4), was better than exendin-4 at correcting hyperglycaemia in rodent models of type 2 diabetes, despite being less efficacious than exendin-4 at promoting insulin secretion. This provides evidence that biased agonists of the GLP-1R may provide novel opportunities for therapeutic intervention [23] .
Exploitation of biased agonism for therapeutic development requires an understanding of the optimal signaling profile for therapeutic benefit while minimizing on-target side effect profiles. While signaling outputs, such as cAMP, calcium and b-arrestin-1 have been linked to insulin secretion and beta cell survival, little is known regarding the optimal activation of these pathways relative to one another or of signaling pathways required for other actions, such as satiety and decreased gastric emptying and glucagon secretion, that are mediated by GLP-1R activation. In addition, signaling outputs that lead to undesired outputs of GLP-1R activation are also unknown. To fully understand these processes requires a toolbox of biased agonists with distinct biased profiles that are suitable for translational in vivo studies.
Recently, we have begun to explore a non-traditional approach to generate new GLP-1 analogues, involving replacement of selected a-amino acid residues with b-amino acid residues (Fig. 1A) [24, 26] . This backbone-modification strategy has produced ''a/b-peptides" that provide resistance to degradation by proteases [36, 37] ; proteolysis can limit the in vivo efficacy of a-peptides. This approach identified b-arrestin-biased GLP-1R agonists (relative to cAMP production) in the context of HEK-293 cells recombinantly expressing the human GLP-1R [24] . Backbone modification has received relatively little attention as an approach to the design of peptide hormone analogues, but holds significant promise for generation of novel peptides [22, 24, [26] [27] [28] [29] [30] [31] [32] [33] .
The ability to detect bias and indeed the observed direction of bias are dependent upon the breadth of endpoints studied and the cellular system used to explore this behavior. While the proximal driver for biased agonism may be at the level of receptor conformation, the expression of this bias (the observed bias) is critically dependent upon the expression, quantity and localization of effector and regulatory proteins within each cellular context. To explore the bias relative to other well characterized biased peptides, such as oxyntomodulin and exendin-4, required profiling these ligands in the same cellular background.
The studies described below provide a new and deeper understanding of the signaling properties of P1-P9 at the GLP-1R by analyzing these peptides in a different cellular context (recombinantly expressed human GLP-1R in CHO cells, in contrast to the HEK293 cells used in previous studies) and extending the pharmacological characterization of these peptides. This includes measuring peptide affinities, and broadening the range of signaling endpoints to include ERK1/2 phosphorylation and intracellular calcium mobilization. These latter endpoints are both relevant to the physiological signaling of the GLP-1R and have been characterized in this cell background in response to other biased agonists of the GLP-1R. Thus, the new data allow direct comparison of biased profiles of the a/b-peptides with bias profiles of previously studied peptides and expands the pharmacological toolbox, providing a wider range of ligands that can be used for exploring the potential of biased GLP-1R profiles for therapeutic advantage.
Materials and methods

Materials
Dulbecco's modified Eagle's medium (DMEM), hygromycin-B, and Fluo-4 acetoxymethyl ester were purchased from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum (FBS) was purchased from Thermo Fisher Scientific (Melbourne, Victoria, Australia). AlphaScreen TM reagents, and LANCE HTRF cAMP kit were purchased from PerkinElmer Life Sciences (Waltham, MA, USA). SureFire TM ERK1/2 reagents were generously supplied by TGR Biosciences (Adelaide, South Australia, Australia). GLP-1 was purchased from Mimotopes (Victoria, Australia).
All other reagents were purchased from Sigma (St. Louis, MO, USA) or BDH Merck (Melbourne, Vic, Australia) and were of an analytical grade.
Peptide synthesis
Peptides were synthesized in house as previously described [24] .
Transfections and cell culture
Wildtype GLP-1R was isogenically integrated into FlpIn-Chinese hamster ovary (FlpInCHO) cells (Invitrogen), and selection of receptor-expressing cells was accomplished by treatment with 600 lg/mL hygromycin-B as previously reported [41] . Transfected and parental FlpInCHO cells were maintained in Dulbecco's modified Eagle's medium supplemented with 5% (v/v) FBS, 600 lg/mL hygromycin-B and incubated in a humidified environment at 37°C in 5% CO 2 . FlpInCHO cells stably expressing the GLP-1R were used at passages 18-32. FlpInCHO cell lines stably expressing GLP-1 receptor-Rluc8 and b-arrestin-1-Venus were used at passages [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . FlpInCHO cell lines stably expressing GLP-1 receptorRluc8 and b-arrestin-2-Venus were used at passages 15-33. HTRF (Homogeneous Time Resolved Fluorescence) for each sample was detected using an EnVision TM plate reader with excitation at 320 nm and emission at 615 nm. cAMP was determined for all samples via conversion to concentration of cAMP using a cAMP standard curve that was detected in parallel. Data were normalized to the maximal response elicited by GLP-1, with 0% representing the concentration of cAMP in the presence of vehicle and 100% representing the concentration of cAMP in the presence of 100 nM GLP-1. 100 lM Forskolin was used as a positive control.
Radioligand binding assays
ERK1/2 phosphorylation
GLP-1R expressing FlpInCHO cells were seeded at a density of 3 Â 10 4 cells/well in DMEM with 5% FBS into 96-well culture plates. The following day, the media were aspirated and the cells were washed twice with 100 lL PBS. 90 lL of serum free DMEM was then added and the cells were incubated overnight at 37°C, 5% CO 2 . Ligand-mediated pERK1/2 was determined using the AlphaScreen TM ERK1/2 SureFire TM protocol as previously described [43] . Prior to generation of concentration response curves, initial pERK1/2 timecourse experiments were performed over 1 h using high concentrations of peptide ligand (1 lM) to determine the time at which pERK1/2 was maximal after stimulation by agonists. Concentration response curves were then generated at this peak time point for each ligand. The kinetics of pERK1/2 response were similar for all ligands, peaking at 6 min. Data were normalized to the maximal response elicited by GLP-1, with 0% representing the RFU measured in the presence of vehicle and 100% representing the RFU measured in the presence of 100 nM GLP-1. 10% FBS, determined at 6 min was used as a positive control. bation, the assay plates were transferred to a Molecular Devices FlexStation (Molecular Devices, Palo Alto, CA, USA) and robotic addition of ligands was performed. Fluorescence was determined immediately after peptide addition, with an excitation wavelength set to 485 nm and an emission wavelength set to 525 nm, and readings were taken every 1.36 s for 120 s. Peak magnitude was calculated using five-point smoothing, followed by correction against basal fluorescence. The peak value was used to create concentration-response curves. Data were normalized to the maximal response elicited by GLP-1, with 0% representing the RFU measured in the presence of vehicle and 100% representing the RFU measured in the presence of 100 nM GLP-1 100 lM ATP was used as a positive control.
Intracellular calcium mobilization
GLP-1R expressing
b-Arrestin recruitment assays
FlpInCHO cell lines stably expressing GLP-1 receptor-Rluc8 and either b-arrestin-1-or b-arrestin-2-Venus were generated using gateway technology. These cell lines were characterized and described previously [44] . Cells were seeded in 96-well white culture plates at a density of 4 Â 10 4 cells/well and cultured for 24 h in DMEM with 5% FBS. Cells were rinsed once with HBSS to remove traces of phenol red and incubated in fresh HBSS for further 15 min. The Rluc substrate coelenterazine-h was added to reach a final concentration of 5 mM. After a 10 min incubation, the corresponding agonist was added and bioluminescence resonance energy transfer (BRET) readings were collected using a LumiSTAR Omega instrument that allows sequential integration of signals detected in the 465-505 and 515-555 nm windows using filters with the appropriate band pass. The BRET signal was calculated by subtracting the ratio of 515-555 nm emission over 465-505 nm emission for a vehicle treated cell sample from the same ratio for the ligand treated cell sample. In this calculation, the vehicle treated cell sample represents background and results are expressed as ligand-induced BRET. This eliminates the requirement for measuring a donor only control sample. Initial time course experiments were performed over 20 min to determine the time at which b-arrestin-1 and b-arrestin-2 recruitment was maximal for each ligand. Subsequent concentration response data were collected at this peak time (2.5 min for all ligands). Data were normalized to the maximal response elicited by GLP-1, with 0% representing the RFU measured in the presence of vehicle and 100% representing the RFU measured in the presence of 100 nM GLP-1.
Data analysis
All data were analyzed using Prism 6 (GraphPad Software Inc., San Diego, CA, USA). For all analyses the data are unweighted and each y value (mean of replicates for each individual experiment) is considered an individual point. To calculate IC 50 , EC 50 and E max values, concentration response signaling data were analyzed as previously described [41] using a three-parameter logistic equation.
Signaling bias was also quantified as previously described by analysis of concentration-response curves for functional data with nonlinear regression using an operational model of agonism modified to directly estimate the ratio of s/K A [24, 25, 41] .
where E m represents the maximal stimulation of the system, K A is the agonist-receptor dissociation constant, in molar concentration,
[A] is the molar concentration of ligand and s is the operational measure of efficacy in the system, which incorporates signaling efficacy and receptor density. All estimated s/K A ratios included propagation of error for both s and K A . Changes in s/K A ratios with respect to GLP-1 for each novel peptide was used to quantitate bias between signaling pathways. Accordingly, bias factors included propagation of error from s/K A ratios of each pathway.
Statistics
Changes in peptide affinity, potency, efficacy or bias of each peptide in comparison to the GLP-1 control were statistically analyzed with a one-way analysis of variance and Dunnett's post test, and significance accepted at p < 0.05.
Results
GLP-1R agonist affinities
We assessed the affinities of GLP-1 and peptides P1-P9 for the GLP-1R expressed in FlpIn CHO cells via competition with a radiolabeled antagonist, 125 I-exendin (9-39) ( Table 1 , Fig. 2A ). The resulting IC 50 values represent an averaged response arising from multiple receptor conformations that are present because individual GLP-1R molecules are presumably engaged by different intracellular partners; in this context the predominant signaling effector complex will have the most impact.
Incorporation of one (P7), three (P1, P8) or four (P2, P9) b amino acid residues, regardless of position, led to a $10-fold reduction in affinity, relative to GLP-1, for the GLP-1R. Addition of a fifth b residue (P3, P4) further reduced affinity by 10-fold relative to other a/b-peptides in this set. a/b-Peptide P4 contains two Aib substitutions, which seem to have little impact on affinity for the GLP-1R, because P3 and P4 are indistinguishable. This conclusion is supported by the observation that a-peptides P5 and P6, which contain one or both of the Aib substitutions in P4, display only slightly reduced affinity for the GLP-1R relative to GLP-1.
Evaluation of cAMP production stimulated by P1-P9
We measured cAMP accumulation in response to P1-P9 in FlpIn CHO cells stably expressing the human GLP-1R (Table 1, Fig. 2B ).
We observed a modest decline in potency arising from a ? b replacement (P1 ? P2, P3), and a further decline upon Aib replacements (P3 ? P4). Peptides P5-P7 were similar in potency to GLP-1, while P8 and P9 displayed substantially reduced potency relative to GLP-1. We previously assessed the activities of P1-P9 in HEK293 cells transiently transfected with the human GLP-1R, using a kinetic GloSensor assay [24, 45] . The cAMP potencies for P1-P9 in the current study using an AlphaScreen assay are similar to those measured in HEK cells using the GloSensor assay [24] . The similarity between these two assays, involving different cell types, provides confidence that the trends are robust.
Evaluation of b-arrestin recruitment stimulated by P1-P9
We assessed b-arrestin-1 and b-arrestin-2 recruitment to the GLP-1R for P1-P9 using b-arrestin-1 and b-arrestin-2 BRET assays in FlpInCHO cells stably expressing GLP-1R-Rluc8 and either b-arrestin-1 or b-arrestin-2-Venus (Table 1, Fig. 2C,D [24] , and the inter-assay differences in peptide behavior are likely due to differences in cellular background (the original BRET assays involved transfected HEK293FT cells, while the new BRET assay were conducted in transfected FlpIn CHO cells) and differential expression of regulatory proteins between the two experiments. The previous BRET assays were conducted with cells that had been co-transfected with GRK5, which enhances the affinity of b-arrestins for GLP-1R by promoting receptor phosphorylation [10, 46] . In contrast, GRK5 was not employed in the current BRET assays; thus, coupling between the receptor and each b-arrestin should be weakened in the new assays relative to the original assays. A second difference is specific to the b-arrestin-2 recruitment assay. The original BRET assay employed a mutated b-arrestin-2 plasmid (R393E, R395E), which is expected to enhance the BRET signal by preventing clathrin binding and subsequent receptor internalization [10, 46] . In contrast, native b-arrestin-2 was used for the current assay.
Intracellular calcium mobilization stimulated by P1-P9
To further explore how the different pathways activated by GLP-1 are affected by a ? b replacements, we measured the abilities of P1-P9 to promote intracellular calcium mobilization, which reports on Ga q and Ga s activation [9, [47] [48] [49] , in FlpIn CHO cells stably expressing the human GLP-1R (Table 1, Fig. 2E ). Overall, a ? b replacements led to a reduction in calcium mobilization. Incorporation of three b-amino acid residues (P1) into the C-terminal region of GLP-1 had the smallest impact on activity, with the decrease in activity becoming more pronounced for analogues containing additional a ? b replacements extending toward the N-terminus of GLP-1 (P2-P4). Incorporation of a single b residue at position 18 (7) led to a slight decrease in activity; further a ? b substitutions in the central region of GLP-1, to generate P9, essentially abolished calcium mobilization. Neither of the two Aib replacements (P5 and P6) had a substantial effect on calcium mobilization in terms of potency or maximum response relative to GLP-1.
Stimulation of ERK1/2 phosphorylation stimulated by P1-P9
As a complement to characterizing the activity of analogues 1-9 in activating various pathways directly mediated by interaction between the GLP-1R and intracellular effector proteins (i.e. G proteins Ga s and Ga q , b-arrestin-1 or b-arrestin-2), we assessed the activity of P1-P9 in promoting ERK1/2 phosphorylation (Table 1, Fig. 2F ). GLP-1-mediated ERK1/2 phosphorylation is dependent on both G protein and b-arrestin activity [9, 11, 12, 49] , which led us to explore how a ? b replacement would affect signaling in this composite pathway, particularly for the b-arrestin-biased a/b-peptides P3, P8 and P9. Our data indicate that ERK1/2 phosphorylation was less strongly affected by a ? b replacements than was cAMP production, b-arrestin recruitment or calcium mobilization.
Stimulus bias induced by P1-P9
To determine whether peptides among P1-P9 display signaling bias relative to GLP-1 in the expanded set of signaling pathways characterized, and to compare any bias between cAMP accumulation and b-arrestin recruitment in the CHO cell background to the b-arrestin bias we observed for a/b-peptides P3, P8 and P9 in the HEK293 cell, we analyzed the efficacy of each analogue in assays for cAMP accumulation, calcium mobilization, ERK1/2 phosphorylation, b-arrestin-1 recruitment or b-arrestin-2 recruitment using the operational model of agonism [50, 51] . Transduction coefficients (log(s/K A )) for each analogue were extracted from concentration-response curves and compared with transduction coefficients for GLP-1 in each effector pathway. These comparisons allowed us to calculate a bias factor (Dlog(s/K A )) for each peptide in terms of calcium mobilization, ERK1/2 phosphorylation, b-arrestin-1 recruitment or b-arrestin-2 recruitment relative to cAMP accumulation (Fig. 3, Table 2 ). We also determined bias factors for each peptide in terms of b-arrestin-1 recruitment or b-arrestin-2 recruitment relative to either calcium mobilization or ERK1/2 phosphorylation (Fig. 3, Table 2 ).
The bias factors summarized in Fig. 3 and Table 2 reveal that a/b-peptides P3, P4, P7, P8 and P9 manifest significant bias in at least one pathway. For example, peptides P3, P7 and P8 are weakly biased toward cAMP accumulation relative to calcium mobilization (Fig. 3A) . Peptides P3, P4 and P9 are biased toward ERK1/2 phosphorylation relative to cAMP accumulation (Fig. 3B ). Peptides P3, P8 and P9 are biased toward b-arrestin-1 recruitment relative to cAMP production (Fig. 3A) . None among P1-P9 displayed bias toward or away from b-arrestin-2 recruitment relative to cAMP accumulation (Fig. 3D) ; however, bias factors could not be calculated for P4, P8 and P9 due to weak b-arrestin-2 responses to these peptides (Fig. 2, Table 1 ). For this reason it was impossible to robustly compare b-arrestin-2 recruitment with other signaling pathways.
Discussion and conclusions
The characterization of P1-P9 in the current study was performed in CHO cells, while our initial studies with these analogues were performed in HEK293 cells; thus, these two studies collectively allow one to assess the impact of cellular background on the manifestation of biased agonism [24] . Moreover, because the current studies evaluate bias for P1-P9 in terms of a more diverse set of signaling and regulatory endpoints relative to the previous study, the data reported here allow a more complete understanding of the activity profiles of these GLP-1 analogues, and these data can be used to compare the bias profiles of P1-P9 to the profiles of known agonists of the GLP-1R.
The bias factors for P1-P9 in terms of b-arrestin recruitment relative to cAMP production, shown in Fig. 4 and Table 2 , are consistent with those of our previous study [24] , particularly for b-arrestin-1 with analogues that display strong bias, such as P8 and P9, biased toward b-arrestin-1 recruitment over cAMP (either accumulation or production) in both sets of experiments and analogues with weaker bias having consistent trends (for example, P3 is significantly biased in the CHO cell background, and trends towards bias in the HEK cells).
In our previous HEK293 studies, P3, P8 and P9 exhibited bias toward b-arrestin-2 recruitment over cAMP production [24] , but in our CHO study b-arrestin-2 recruitment could not be detected for these a/b-peptides. The previous system was engineered to enhance b-arrestin-2 coupling through a combination of overexpression of GRK5 and mutation (R393E, R395E) of the arrestin that enhance the BRET signal by preventing clathrin binding and subsequent receptor internalization [10, 46] . In the current assay, we examined recruitment of native b-arrestin-2, which was poorly recruited by lower-efficacy peptides. The lack of quantitative signal for these peptides makes interpretation of potential changes to signaling bias between the two cell types problematic. Overall, the pattern of bias changes in the enhanced b-arrestin-2 assay in HEK293 cells, along with the b-arrestin-1 profiles in both CHO and HEK cells, indicates fundamental differences in the properties of the P3, P8 and P9 a/b-peptides relative to GLP-1 itself. Comparing the bias profiles of P1-P9 between CHO and HEK293 cells highlights that the utility of using recombinant systems lies in probing bias and in fingerprinting the activity profiles of different agonists, but not in making specific claims about the relevance of observed bias to physiological effects manifested in native cells and whole organisms.
Expanding the diversity of pharmacological parameters assessed in the current study, relative to the previous report, reveals that all of our a/b-peptides had significantly lower affinity compared to GLP-1 and more extensive bias was observed within P1-P9 beyond bias toward b-arrestin recruitment over cAMP ( Table 2, Fig. 3 ). Substitutions that only marginally altered ligand affinity (approx. 3-fold for P5 and P6) did not display biased agonism, whereas a/b substituted peptides with >10-fold lower affinity than GLP-1 all had some observed bias. However, there was no correlation between the measured affinity and the biased agonism profile of these peptides.
Among P3, P4, P7, P8 and P9, each a/b-peptide manifests significant bias in at least one pathway. P3, P7 and P8 are all weakly biased toward cAMP accumulation relative to calcium mobilization, though these analogues are only weakly active in both pathways. P3, P4 and P9 are biased toward ERK1/2 phosphorylation over cAMP accumulation; weak but statistically insignificant trends of this type are observed for other peptides, including P2 and P8. Overall, backbone modification has only limited impact on ERK1/2 phosphorylation, leading to bias towards this pathway over those for which substantial changes in response are observed. The pathway that most closely parallels the trend in bias for ERK1/2 phosphorylation is b-arrestin-1 recruitment, toward which P3, P8 and P9 are biased over cAMP accumulation. The ERK1/2 phosphorylation signal in CHO cells is a composite of b-arrestinand G protein-dependent signaling [9, 11, 12] , and the correlation between ERK1/2 phosphorylation bias and b-arrestin-1 bias suggests that the arrestin pathway is predominant for P3, P8 and P9 for causing ERK1/2 phosphorylation. However, the proposed b-arrestin pathway dominance may not pertain to all a/bpeptides. Among the ERK1/2 phosphorylation-biased compounds, P4 is the most strongly biased toward ERK1/2 phosphorylation over cAMP production, but P4 caused no measurable signal in the b-arrestin-recruitment assays, despite the robust pERK1/2 response. Understanding the relative bias of P4 for ERK1/2 phosphorylation versus b-arrestin recruitment will require more sensitive assays of b-arrestin recruitment.
Some among P1-P9 display selective bias toward or away from either b-arrestin-1 recruitment or b-arrestin-2 recruitment when compared with various other pathways. P6, for example, is biased toward b-arrestin-1 recruitment over calcium mobilization, but does not favor b-arrestin-2 recruitment over calcium mobilization. and HEK293 cells [24] (B) and for b-Arrestin-2 recruitment versus cAMP accumulation between FlpInCHO cells (C) and HEK293 cells [24] (D). Changes in log (s/K A ) were calculated to provide a measure of the degree of stimulus bias exhibited between different signaling pathways relative to that of the reference agonist GLP-1. * statistically significantly different from GLP-1 using a one way analysis of variance followed by Dunnett's test (P < 0.05). Table 2 Stimulus bias exhibited by a-and a/b-peptides P1-P9 relative to the reference agonist GLP-1. Several well-studied peptides, including exendin-4 and oxyntomodulin, have been identified as biased agonists of the GLP-1R [9, 20, 21, 25] . Both exendin-4 and oxyntomodulin bias the GLP-1R toward b-arrestin-1 recruitment and b-arrestin-2 recruitment over cAMP accumulation in experiments performed in FlpIn CHO cells [9, 20, 25] . Oxyntomodulin also biases the GLP-1R toward ERK1/2 phosphorylation over cAMP accumulation, but exendin-4 does not exhibit bias toward ERK1/2 phosphorylation [9, 20, 25] . The observation that exendin-4 and oxyntomodulin are both biased toward b-arrestin recruitment but only oxyntomodulin is also biased toward ERK1/2 phosphorylation may be explained by different degrees of contribution from b-arrestin-1 and b-arrestin-2 activity in mediating downstream ERK1/2 phosphorylation [9] . The distinct bias profiles for these two peptides indicate different modes of activation of the GLP-1R in response to either oxyntomodulin or exendin-4.
Dlog(s/K
Because the bias factors calculated for P1-P9 in this work are derived from experiments performed in the same FlpIn CHO cells that were used in the experiments to determine bias for exendin-4 and oxyntomodulin, the bias for P1-P9 can be compared to that observed for exendin-4 and oxyntomodulin without concerns that either differences in cellular background or in assay format are the cause of distinct bias profiles between discrete agonists. Fig. 5 provides a graphical summary of bias effects that allows ready comparison of P1-P9 (Fig. 5A, B) or exendin-4 [9] and oxyntomodulin [9] (Fig. 5C ) with GLP-1 in terms of all five of the GLP-1R signaling outcomes we monitored. Each ''web of bias" is constructed to convey bias relative to the cAMP production pathway. P4 is illustrated in both Fig. 5A , which highlights ERK1/2 phosphorylation-biased ligands, and 5B as a reference for the a/b peptides.
Comparing the bias profiles for oxyntomodulin and exendin-4 to those for P3, P4, P8 and P9, which each display significant bias toward either b-arrestin-1 or ERK1/2 phosphorylation or both over cAMP [9, 24, 25] , we can categorize each GLP-1 analogue as being either ''oxyntomodulin-like" or ''exendin-4-like" in terms of its bias profile. (This categorization is imperfect, because both oxyntomodulin and exendin-4 are also biased toward b-arrestin-2 over cAMP [9, 25] , while no b-arrestin-2 bias factors could be calculated for any among P3, P4, P8 or P9.) P3 and P9 are both biased toward b-arrestin-1 and ERK1/2 phosphorylation over cAMP, making them ''oxyntomodulin-like" biased agonists of the GLP-1R. P8 is biased toward b-arrestin-1 over cAMP but not toward ERK1/2 phosphorylation over cAMP, and is therefore an ''exendin-4-like" biased agonist of the GLP-1R. The differences in bias profiles for P8 compared to P3 and P9 indicate that these sets of analogues differ in how they activate the GLP-1R. P4 is biased toward ERK1/2 phosphorylation over cAMP production, but no bias factor could be determined for P4 in terms of b-arrestin-1 over cAMP; thus, the bias profile of P4 is unique because it differs from the profile of either exendin-4 or oxyntomodulin.
We have previously shown that modifying the backbone of GLP-1 via incorporation of b-amino acid residues can generate agonists that engender significant bias toward b-arrestin-1 and/ or b-arrestin-2 recruitment over cAMP production relative to GLP-1 itself [24] . Here, we expand the characterization of these biased peptides to include receptor-affinity measurements and additional signaling endpoint measurements. Our new data show that several among the a-and a/b-peptides we characterized are biased toward additional signaling outcomes beyond b-arrestin recruitment, thereby highlighting the importance of monitoring a diverse set of signaling and regulatory endpoints when characterizing novel agonists to identify biased agonists. These new results strengthen the conclusion that a ? b residue replacement can alter receptor signaling relative to the parent a-peptide. Thus, a ? b residue replacement may prove to be a general method by which receptor selectivity can be engineered into a peptide agonist that activates its cognate receptor to initiate different signaling pathways. The a/b-peptides characterized in this work may have utility as tools to probe the roles of b-arrestin recruitment and ERK1/2 phosphorylation in GLP-1R signaling. Moreover, these a/ b-peptides could provide a platform to develop pathwayselective therapeutic agents targeting the GLP-1R.
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